NDLI: A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

Please wait, while we are loading the content...

A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

Increased Cerebral Oxygen Metabolism and Ischemic Stress in Subjects with Metabolic Syndrome-Associated Risk Factors: Preliminary Observations

Sublethal Transient Global Ischemia Stimulates Migration of Neuroblasts and Neurogenesis in Mice

VEGF Induces More Severe Cerebrovascular Dysplasia in Eng$^{+/−}$ than in Alk1$^{+/−}$ Mice

The Akt Pathway Is Involved in Rapid Ischemic Tolerance in Focal Ischemia in Rats

Evidence for a Predominant Intrinsic Sympathetic Control of Cerebral Blood Flow Alterations in an Animal Model of Cerebral Arteriovenous Malformation

Quantitative Temporal Profiles of Penumbra and Infarction During Permanent Middle Cerebral Artery Occlusion in Rats

Translational Stroke Research : Volume 1, Issue 2, June 2010

Translational Stroke Research : Volume 1, Issue 1, March 2010

A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

Content Provider	Springer Nature Link
Author	Mandava, Pitchaiah Dalmeida, William Anderson, Jane A. Thiagarajan, Perumal Fabian, Roderic H. Weir, Raymond U. Kent, Thomas A.
Copyright Year	2010
Abstract	Thrombolysis remains a mainstay in the treatment of ischemic stroke. While not usually considered in the spectrum of clot lysis, experimental data show that inhibition of the platelet glycoprotein (GP) IIb/IIIa receptor can reduce as well as reverse thrombus formation and improve microvascular flow in stroke models. However, a recent clinical trial of GP IIb/IIIa inhibition in stroke did not demonstrate clinical benefit and was associated with increased hemorrhage. Based on an understanding of the relationship between GP IIb/IIIa receptor inhibition, efficacy and hemorrhage, we hypothesized that a lower dose of abciximab would achieve a favorable range of platelet inhibition and potentially good clinical outcomes. Forty-four patients with suspected large vessel occlusion, who were not eligible for rt-PA were offered treatment with approximately 30% lower total dose of intravenous abciximab if within 6 h for anterior circulation or 24 h for posterior circulation stroke (later modified to 12 h). Concomitant anticoagulation, usually with unfractionated heparin was employed. The extent of platelet inhibition was measured in 21 patients. Hemorrhage rate and 90-day functional outcomes and mortality were obtained. A matching algorithm involving finding the nearest neighbor from individual subjects in the control arm of the NINDS rt-PA database was used to compare outcomes at similar baseline characteristics and gender. Mean platelet inhibition was 92.1 ± 6.7% vs inhibition reported with percutaneous coronary intervention (PCI) of 96 ± 10; p = 0.08. Successful matching to NINDS controls was accomplished: after outlier elimination, median and mean NIHSS of the abciximab subjects compared to NINDS controls was 16.5 vs 15.5 (p = 0.92) and 16.3 vs 16.0 (p = 0.86). Mean age was 67.2 vs 67.1 (p = 0.97). Mean glucose was 141 vs 142 (p = 0.92). There was one symptomatic hemorrhage; minor hemorrhages occurred in 9%. The percent of patients who achieved an mRS 0–2 or died in the treated vs matched NINDS control patients was 63 vs 38 (p = .02) and 23 vs 23 (p = 1.0). Our pilot results indicated that a lower dose of abciximab results in platelet inhibition similar to that achieved in the coronary vascular bed during PCI. Comparison to matched historical controls suggests that this lower dose in combination therapy may be safe and effective therapy for thrombotic stroke and a randomized trial is warranted.
Starting Page	170
Ending Page	177
Page Count	8
File Format	PDF
ISSN	18684483
Journal	Translational Stroke Research
Volume Number	1
Issue Number	3
e-ISSN	1868601X
Language	English
Publisher	Springer-Verlag
Publisher Date	2010-05-20
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Glycoprotein IIB/IIIA receptor antagonists GP IIB/IIIA inhibitors Abciximab Platelet aggregation units Platelet function inhibition Ischemic stroke Matching algorithm Vascular Surgery Neurosurgery Cardiology Neurology Neurosciences
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine Neuroscience Neurology (clinical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke

Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition

Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials

Review Platelet glycoprotein IIb/IIIa receptor blockade in coronary (2001)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction.

Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary.

Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes

Economic assessment of platelet glycoprotein iib/iiia receptor blockade with abciximab and low-dose heparin.

A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice

Similar Documents

Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke

Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition

Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials

Review Platelet glycoprotein IIb/IIIa receptor blockade in coronary (2001)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction.

Platelet glycoprotein IIb/IIIa inhibitors in acute ischemic stroke

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary.

Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes

Economic assessment of platelet glycoprotein iib/iiia receptor blockade with abciximab and low-dose heparin.

A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice